

DEPRENYL INC., DELAWARE, USA

Balance Sheet As at 31st March,	Note No	2014		2013	
		USD	₹ in 000's	USD	₹ in 000's
I. EQUITY AND LIABILITIES					
Shareholders' Funds					
Share Capital	1	15	1	15	1
Reserves & Surplus	2	29,66,721	1,77,736	30,14,679	1,63,668
		29,66,736	1,77,737	30,14,694	1,63,669
Non-current liabilities					
Deferred tax liabilities(Net)	3	4,59,000	27,499	4,05,450	22,012
		4,59,000	27,499	4,05,450	22,012
Current liabilities					
Other Current liabilities	4	2,87,603	17,230	4,13,638	22,456
		2,87,603	17,230	4,13,638	22,456
Total		37,13,339	2,22,466	38,33,782	2,08,137
II. ASSETS					
Non-current assets					
Fixed Assets					
Intangible Assets		13,50,000	80,879	13,50,000	73,292
Long-term loans and advances	5	98,505	5,901	20,250	1,099
		14,48,505	86,780	13,70,250	74,391
Current Assets					
Trade receivables	6	-	-	90,759	4,928
Cash & Cash equivalents	7	8,212	492	3,14,309	17,064
Short-term loans and advances	8	22,56,622	1,35,194	20,58,463	1,11,754
		22,64,834	1,35,686	24,63,531	1,33,746
Total		37,13,339	2,22,466	38,33,781	2,08,137

Rajneesh Gupta
Head Accounts

Place : Noida
Date : 23 May 2014

DEPRENYL INC., DELAWARE, USA

Statement of Profit & Loss for the year ended 31st March,	Note No	2014		2013	
		USD	₹ in 000's	USD	₹ in 000's
REVENUE					
Revenue from operations(net)	9	(86,328)	(5,089)	3,87,835	21,079
Other Income	10	98,345	5,943	87,114	4,735
Total Revenue		12,017	854	4,74,949	25,814
EXPENSES					
Other expenses	11	84,680	4,991	2,10,739	11,454
Total Expenses		84,680	4,991	2,10,739	11,454
Profit Before Tax		(72,663)	(4,137)	2,64,210	14,360
Tax expenses:					
- Current Tax		(78,255)	(4,832)	(1,34,691)	(7,320)
- Deferred Tax Charge		53,550	3,235	1,15,640	6,285
		(24,705)	(1,597)	(19,051)	(1,035)
Profit/(Loss) for the year		(47,958)	(2,540)	2,83,261	15,395

Rajneesh Gupta
Head Accounts

Place : Noida
Date : 23 May 2014

DEPRENYL INC., DELAWARE, USA

Cash Flow Statement for the year ended 31st March,	2014		2013	
	USD	₹ in 000's	USD	₹ in 000's
A. Cash Flow arising from Operating Activities :				
Net profit before tax	(72,663)	(4,390)	2,64,210	14,360
Adjustments for:				
Interest Income	(98,345)	(5,941)	(87,114)	(4,735)
Operating Profit before Working Capital Changes	(1,71,008)	(10,331)	1,77,096	9,625
Adjustments for :				
(Increase)/Decrease in Trade & Other Receivables	90,759	5,483	2,89,632	15,741
Increase/(Decrease) in Current Liabilities	(1,26,035)	(7,614)	2,91,820	15,860
Cash generated from Operations	(2,06,284)	(12,462)	7,58,548	41,226
Direct Taxes Paid	-	-	(81,130)	(4,409)
Net Cash Inflow/(Outflow) in course of Operating Activities	(2,06,284)	(12,462)	6,77,418	36,817
B. Cash Flow arising from Investing Activities :				
Loans to related parties	(1,00,000)	(6,041)	(6,50,000)	(35,328)
Interest Received	187	11	146	8
Net Cash Inflow/(Outflow) in course of Investing Activities	(99,813)	(6,030)	(6,49,854)	(35,320)
C. Foreign Currency Translation Difference arising on Conversion		1,920		979
Net Increase in Cash & Cash equivalents (A+B+C)	(3,06,097)	(16,572)	27,564	2,476
Add: Cash & Cash Equivalents at the beginning of Year	3,14,309	17,064	2,86,745	14,588
Cash & Cash Equivalents at the end of the Year	8,212	492	3,14,309	17,064

Rajneesh Gupta
Head Accounts

Place : Noida
Date : 23 May 2014

DEPRENYL INC., DELAWARE, USA

Notes to the financial statements for the year ended 31st March,	2014		2013	
	USD	₹ in 000's	USD	₹ in 000's
1. SHARE CAPITAL				
Authorized				
3000 Equity Shares of USD 0.01 each	30		30	
	30		30	
Issued, Subscribed & Paid up				
1500 Equity Shares of USD 0.01 each	15	1	15	1
	15	1	15	1

1.1) The Company has only one class of shares referred to as equity shares having par value of USD 0.01. Each holder of equity shares is entitled to one vote per share.

1.2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

1.3) The details of shareholders holding more than 5% shares as at 31st March, 2014 is set out below:

Name of the shareholder	No. of shares	% holding in the class	No. of shares	% holding in the class
Draximage Ltd., Cyprus, Holding Company	1,500	100%	1,500	100%

1.4) The reconciliation of the number of shares outstanding as at 31st March, 2014 and 31st March, 2013 is set out below:

Particulars	As at 31 March 2013		As at 31 March 2012	
	No	₹ in 000's	No	₹ in 000's
Numbers of shares at the beginning	1,500	1	1,500	1
Add: Shares issued during the year	-	-	-	-
Numbers of shares at the end	1,500	1	1,500	1

1.5) Shares held by holding company/ultimate holding company and/or their subsidiaries/associates

Out of the equity Shares issued by the company, shares held by its holding company/ultimate holding company and/or their subsidiaries/associates are as below:

Particulars	As at 31 March 2013		As at 31 March 2012	
	No of shares	₹ in 000's	No of shares	₹ in 000's
Draximage Ltd., Cyprus, Holding Company	1,500	1	1,500	1

DEPRENYL INC., DELAWARE, USA

Notes to the financial statements for the year ended 31st March,	2014		2013	
	USD	₹ in 000's	USD	₹ in 000's
2 RESERVES AND SURPLUS				
Securities Premium Account				
Opening Balance	14,00,085	69,892	14,00,085	69,892
Add: Premium on shares issued during the year	-	-	-	-
	14,00,085	69,892	14,00,085	69,892
Foreign Currency Translation Reserve				
Opening Balance	-	24,237	-	14,926
Add/(Less): Effect of foreign exchange rate variation during the year	-	16,609	-	9,311
Closing Balance	-	40,846	-	24,237
Surplus/(Deficit)				
Opening Balance	16,14,594	69,538	13,31,333	54,143
Add: Net Profit / (Deficit) for the year transferred from Statement of Profit & Loss	(47,958)	(2,540)	2,83,261	15,395
	15,66,636	66,998	16,14,594	69,538
	29,66,721	1,77,736	30,14,679	1,63,668
3 DEFERRED TAX LIABILITY (NET)				
Deferred Tax Liabilities	4,59,000	27,499	4,05,450	22,012
Deferred Tax Assets (Refer Note No 15)	-	-	-	-
Deferred Tax Liabilities(Net)	4,59,000	27,499	4,05,450	22,012
4 OTHER CURRENT LIABILITIES				
Other Payables	2,87,603	17,230	4,13,638	22,456
	2,87,603	17,230	4,13,638	22,456
5. LONG TERM LOANS AND ADVANCES				
Advance payment of income tax/Wealth tax(including TDS)	98,505	5,901	20,250	1,099
	98,505	5,901	20,250	1,099

DEPRENYL INC., DELAWARE, USA

Notes to the financial statements for the year ended 31st March,	2014		2013	
	USD	₹ in 000's	USD	₹ in 000's
6. TRADE RECEIVABLES				
Outstanding for period less than six months from the date they are due for payment				
Secured, considered good	-	-	-	-
Unsecured, considered good (Royalty Receivable)	-	-	90,759	4,928
Doubtful				
Provision for doubtful receivables		-		-
	-	-	90,759	4,928
7. CASH AND CASH EQUIVALENTS				
Balances with banks:				
- On Current Accounts	8,212	492	3,14,309	17,064
	8,212	492	3,14,309	17,064
8. SHORT TERM LOANS AND ADVANCES				
- Loans and advances to related parties (unsecured, considered good)	20,00,000	1,19,820	19,00,000	1,03,151
- Advance recoverable in cash & kind				
- From related parties	2,56,622	15,374	1,58,463	8,603
	22,56,622	1,35,194	20,58,463	1,11,754

DEPRENYL INC., DELAWARE, USA

Notes to the Accounts for the year ended 31st March,	2014		2013	
	USD	₹ in 000's	USD	₹ in 000's
9. REVENUE FROM OPERATIONS				
Royalty Income	(86,328)	(5,089)	3,87,835	21,079
	(86,328)	(5,089)	3,87,835	21,079
10. OTHER INCOME				
Interest Income	98,345	5,943	87,114	4,735
	98,345	5,943	87,114	4,735
11. OTHER EXPENSES				
Bank Charges	25	1	50	3
Legal , Professional & Consultancy Charges	84,655	4,990	2,10,689	11,451
	84,680	4,991	2,10,739	11,454